GENEVA, Switzerland, July 9, 2026
MindMaze Therapeutics Holding SA has announced its support for a University of Pittsburgh clinical study evaluating an innovative combination therapy for post-stroke recovery, pairing cervical epidural spinal cord stimulation (SCS) with the company’s AI-powered precision neurotherapeutics platform. The study seeks to determine whether combining high-dose, high-intensity neurotherapy with spinal cord stimulation can produce lasting improvements in upper limb function for patients recovering from chronic stroke. Building on previously published research demonstrating that cervical spinal cord stimulation can rapidly improve arm and hand movement during active stimulation, the new investigation focuses on whether intensive rehabilitation delivered alongside stimulation can strengthen neural pathways and produce durable neurological recovery. The collaboration reflects MindMaze Therapeutics’ strategy of advancing combination neurotherapies that integrate digital therapeutics with innovative medical technologies to improve long-term functional outcomes in neurological disorders.
Combination Therapy Targets Long-Term Stroke Rehabilitation
The clinical study is based on earlier independent research from the University of Pittsburgh, published in Nature Medicine, which demonstrated that cervical spinal cord stimulation could restore meaningful arm and hand movement in patients with chronic stroke after only a few hours of training. However, the initial improvements were primarily observed while electrical stimulation remained active. The newly launched study investigates whether pairing the same stimulation technology with high-volume, intent-driven neurotherapy can reinforce weakened neural connections and extend recovery beyond the stimulation period.
MindMaze’s precision neurotherapeutics platform delivers intensive rehabilitation through advanced software, proprietary sensors, and artificial intelligence-driven analytics, enabling patients to complete a high volume of targeted therapeutic exercises without increasing demands on clinical staff. Researchers believe repeated pairing of patient movement intention with spinal cord stimulation may enhance neuroplasticity, strengthen motor pathways, and improve long-term recovery of upper limb function following stroke.
Study Expands Precision Neurotherapeutics Research
Advertisement
The University of Pittsburgh study (ClinicalTrials.gov Identifier: NCT07153536) plans to enroll 20 adults living with chronic upper limb weakness following stroke. Participants will first complete a six-week course of intensive neurotherapy, followed by implantation of the spinal cord stimulation system before repeating the rehabilitation program with stimulation active throughout every therapy session. Patients will then be monitored for up to six months to evaluate the durability of neurological improvements achieved through the combined intervention. MindMaze Therapeutics believes this research represents an important step toward integrating precision digital therapeutics with implantable medical technologies and future pharmaceutical interventions to create more effective rehabilitation strategies.
The company’s FDA-listed and CE-marked neurotherapeutic solutions are already designed to support patients recovering from stroke, Parkinson’s disease, and other neurological disorders by providing scalable rehabilitation across hospital, outpatient, and home settings. The collaboration with the University of Pittsburgh highlights the growing role of combination neurotherapies in modern neurological rehabilitation, where advanced medical devices, artificial intelligence, and intensive digital therapy are being combined to maximize functional recovery while addressing the global shortage of specialized rehabilitation professionals. If successful, the study could establish a new therapeutic model capable of improving long-term outcomes for stroke survivors who have reached recovery plateaus using conventional rehabilitation alone.
Source: MindMaze Therapeutics press release
